Расширенный поиск

Отказ от курения у больных с респираторными заболеваниями: первоочередной компонент лечения

Полный текст:

Список литературы

1. Postma D.S., Siafakas N.M., eds. Management of chronic obstructive pulmonary disease. Eur. respir. Mon 1998; 7.

2. Global initiative for chronic obstructive lung disease. NHLBI / WHO Workshop. US Deptartment of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute. NIH Publication № 2701A. Bethesda: National Institutes of Health, 2001.

3. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1: 1645-1648.

4. Fletcher C., Peto R., Tinker C., Speizer F.E., eds. The natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press; 1976.

5. Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J.A.M.A. 1994; 272: 1497-1505.

6. Hand S., Edwards S., Campbell I.A., Cannings R. Controlled trial of three weeks nicotine replacement in hospital patients also given advice and support. Thorax 2002; 57: 715-718.

7. Borson S., Claypoole K., McDonald G.J. Depression and chronic obstructive pulmonary disease: treatment trials. Semin. Clin. Neuropsychiatry 1998; 3: 115-130.

8. Tashkin D.P., Kanner R., Bailey W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575.

9. Fiore M.C., Bailey W.C., Cohen S.J. et al. Smoking cessation: clinical practice guidelines № 18. Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication № 96-0692. Rockville: US Department of Health and Human Services; 1996.

10. Fiore M., Bailey W., Cohen S. et al. Treating tobacco use and dependence: clinical practice guideline. Rockville: US Department of Health and Human Services: 2000.

11. The tobacco use and dependence clinical practice guideline panel, staff and consortium representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. J.A.M.A. 2000; 283: 3244-3254.

12. Anderson J.E., Jorenby D.E., Scott W.J., Fiore M.C. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121: 932-941.

13. American College of Chest Physicians, American Thoracic Society, European Respiratory Society, Asian Pacific Society of Respirology, Canadian Thoracic Society, International Union Against Tuberculosis and Lung Disease. Smoking and health: the physician's responsibility. A statement by the Health and Smoking Committee. Pneumologie 1996; 50: 270-274.

14. Hughes J.R., Fiester S., Goldstein M.G. et al. The American Psychiatric Association practice guidelines for the treatment of patients with nicotine dependence. Am. J. Psychiatry 1996; 153: (suppl. 10): S1-S31.

15. Haustein K.O. Tobacco or health? Berlin: Springer-Verlag, 2001. 34-43.

16. Batra V., Patkar A.A., Berrettini W.H. et al. The genetic determinants of smoking. Chest 2003; 123: 1730-1739.

17. Watkins S.S., Koob G.F., Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob. Res. 2000; 2: 19-37.

18. US Department of Health and Human Services. Nicotine addiction. A report of the Surgeon General. Rockville: US Department of Health and Human Services; 1998.

19. World Health Organization. International classification of diseases, 10th ed. Geneva: World Health Organization; 1992.

20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington: American Psychiatric Association; 1994.

21. Hughes J.R., Gust S.W., Skoog K. et al. Symptoms of tobacco withdrawal. A replication and extension. Arch. Gen. Psychiatry 1991; 48: 52-59.

22. Shiffman S., West R.J., Gilbert D.G. SRNT Work Group on the Assessment of Craving and Withdrawal in Clinical Trials. Nicotine Tob. Res. 2004; 6: 599-614.

23. The World Bank. Curbing the Epidemic: Governments and the Economics of Tobacco Control. Washington; The World Bank, 1999. Available at Date last accessed: March 15, 2005. Date last updated: 2001.

24. Tobacco Policy in the European Union: ASH Fact Sheet № 20. Date last accessed: November 28, 2005. Date last updated: May 2006.

25. Doxa. Indagine sul fumo in Italia 2004. italiano/inchieste/fumo2004_ita.pdf. Date last accessed: March 15, 2005. Date last updated: April 2004.

26. Murin S., Bilello K.S., Matthay R. Other smoking-affected pulmonary diseases. Clin. Chest Med. 2000; 21: 121-137.

27. US Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General, 2004. Date last accessed: November 28, 2006. Date last updated: February 15, 2006.

28. Peto R., Lopez A.D., Boreham J. et al. Mortality from smoking worldwide. Br. Med. Bull. 1996; 52: 12-21.

29. Ezzati M., Lopez A.D. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362: 847-852.

30. Rodu B., Cole P. The burden of mortality from smoking: comparing Sweden with other countries in the European Union. Eur. J. Epidemiol. 2004; 19: 129-131.

31. Doll R., Peto R., Boreham J., Sutherland I. Mortality in relation to smoking: 50 years observations on male British doctors. Br. Med. J. 2004; 328: 1529-1533.

32. Lung cancer. In: European Respiratory Society / European Lung Foundation. European lung white book. The first comprehensive survey on respiratory health in Europe. Sheffield: ERS Journals; 2003. 44-54.

33. La Vecchia C., Franceschi S., Levi F. Epidemiological research on cancer with a focus on Europe. Eur. J. Cancer Prev. 2003; 12: 5-14.

34. Alberg A.J., Samet J.M. Epidemiology of lung cancer. Chest 2003; 123 (suppl. 1): 21S-49S.

35. Flanders W.D., Lally C.A., Zhu B.P. et al. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res. 2003; 63: 6556-6562.

36. Simonato L., Agudo A., Ahrens W. et al. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of interountry heterogeneity. Int. J. Cancer 2001; 91: 876-887.

37. Murray C.J.L., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.

38. Chronic obstructive pulmonary disease. In: European Respiratory Society / European Lung Foundation. European lung white book. the first comprehensive survey on respiratory health in Europe. Sheffield: ERS Journals; 2003. 34-43.

39. Burney P., Suissa S., Soriano J.B. et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur. Respir. J. 2003; 22 (suppl. 42): 1s-44s.

40. Wedzicha J.A., Donaldson G.C. Exacerbations of chronic obstructive pulmonary disease. Respir. Care 2003; 48: 1204-1213.

41. Viegi G., Pedreschi M., Baldacci S. et al. Prevalence rates of respiratory symptoms and diseases in general population samples of North and Central Italy. Int. J. Tuberc. Lung Dis. 1999; 3: 1034-1042.

42. Lundback B., Lindberg A., Lindstrom M. et al. Obstructive lung disease in Northern Sweden studies. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir. Med. 2003; 97: 115-122.

43. de Marco R., Accordini S., Cerveri I. et al., for the European Community Respiratory Health Survey (ECRHS) Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59: 120-125.

44. Jimenez-Ruiz C.A., Masa F., Miravittles M. et al. Differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365-1370.

45. Watson L., Boezen H.M., Postma D.S. Differences between males and females in the natural history of asthma and COPD. In: Buist S., Mapp C.E., eds. Respiratory diseases in women. Eur. Respir. Mon. 2003; 25: 50-73.

46. Viegi G., Scognamiglio A., Baldacci S. et al. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001; 68: 4-19.

47. Calverley P.M.A., Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362: 1053-1061.

48. Willemse B.W.M., Postma D.S., Timens W., ten Hacken N.H.T. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur. Respir. J. 2004; 23: 464-476.

49. Anthonisen N.R., Skeans M.A., Wise R.A. et al., for the Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality. Ann. Intern. Med. 2005; 142: 233-239.

50. Cerveri I., Accordini S., Corsico A. et al., for the ISAYA Study Group. Chronic cough and phlegm in young adults. Eur. Respir. J. 2003; 22: 413-417.

51. Carrozzi L., Rijcken B., Burney P. et al. Family history for chronic lung diseases and epidemiological determinants of COPD in three European countries. Eur. Respir. Rev. 2001; 11: 49-54.

52. Eagan T.M.L., Gulsvik A., Eide G.E., Bakke P.S. Remission of respiratory symptoms by smoking and occupational exposure in a cohort study. Eur. Respir. J. 2004; 23: 589-594.

53. Kerstjens H.A.M., Rijcken B., Schouten J.P., Postma D.S. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 1997; 52: 820-827.

54. Gold D.R., Wang X., Wypij D. et al. Effects of cigarette smoking on lung function in adolescent boys and girls. N. Engl. J. Med. 1996; 335: 931-937.

55. Sherrill D.L., Lebowitz M.D., Knudson R.J., Burrows B. Smoking and symptom effects on the curves of lung function growth and decline. Am. Rev. Respir. Dis. 1991; 144: 17-22.

56. Xu X., Weiss S.T., Rijcken B., Schouten J.P. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur. Respir. J. 1994; 7: 1056-1061.

57. Downs S.H., Brandli O., Zellweger J.P. et al. Accelerated decline in lung function in smoking women with airway obstruction: SAPAL-DIA 2 cohort study. Respir. Res. 2005; 6: 45.

58. Anthonisen N.R., Connett J.E., Murray R.P. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med. 2002; 166: 675-679.

59. Scanlon P.D., Connett J.E., Waller L.A. et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 2000; 161: 381-390.

60. Sherrill D.L., Enright P., Cline M. et al. Rates of decline in lung function among subjects who restart cigarette smoking. Chest 1996; 109: 1001-1005.

61. Murray R.P., Anthonisen N.R., Connett J.E. et al. Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. Lung Health Study Research Group. J. Clin. Epidemiol. 1998; 51: 1317-1326.

62. Bolliger C.T., Zellweger J.P., Danielsson T. et al. Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob. Res. 2002; 4: 433-439.

63. Viegi G., Paoletti P., Carrozzi L. et al. CO diffusing capacity in a general population sample: relationships with cigarette smoking and airflow obstruction. Respiration 1993; 60: 155-161.

64. Viegi G., Sherrill D.L., Carrozzi L. et al. An 8year followup of carbon monoxide diffusing capacity in a general population sample of northern Italy. Chest 2001; 120: 74-80.

65. Viegi G., Matteelli G., Annesi I. Epidemiology of asthma. In: Chung F., Fabbri L.M., eds. Asthma. Eur. Respir. Mon. 2003; 23: 1-25.

66. Ulrik C.S., Lange P. Cigarette smoking and asthma. Monaldi Arch. Chest Dis. 2001; 56: 349-353.

67. Thomson N.C., Chaudhuri R., Livingston E. Asthma and cigarette smoking. Eur. Respir. J. 2004; 24: 822-833.

68. Doll R. Risk from tobacco and potentials for health gain. Int. J. Tuberc. Lung Dis. 1999; 3: 90-99.

69. To/nnesen P., Pisinger C., Hvidberg S. et al. Effects of smoking cessation and reduction in asthmatics. Nicotine Tob. Res. 2005; 7: 139-148.

70. Farr B.M., Bartlett C.L., Wadsworth J., Miller D.L. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir. Med. 2000; 94: 954-963.

71. Almirall J., Gonzalez C.A., Balanzo X., Bolibar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999; 116: 375-379.

72. Nuorti J.P., Butler J.C., Farley M.M. et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N. Engl. J. Med. 2000; 342: 681-689.

73. Arcavi L., Benowitz N.L. Cigarette smoking and infection. Arch. Intern. Med. 2004; 164: 2206-2216.

74. Gajalakshmi V., Peto R., Kanaka T.S., Jha P. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43 000 adult male deaths and 35 000 controls. Lancet 2003; 362: 507-515.

75. Baumgartner K.B., Samet J.M., Stidley C.A. et al. Collaborating Centers. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1997; 155: 242-248.

76. Chiyo M., Sekine Y., Iwata T. et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and longterm outcomes. J. Thorac. Cardiovasc. Surg. 2003; 126: 1141-1146.

77. Henry M., Arnold T., Harvey J. on behalf of the BTS Pleural Disease Group, a subgroup of the BTS Standards of Care Committee. BTS guidelines for the management of spontaneous pneumothorax. Thorax 2003; 58 (suppl. II): 39-52.

78. Rollnick S., Mason P., Butler C. Health behaviour change: a guide for practitioners. London, Churchill Livingstone, 1999.

79. Fagerström K.O. Time to first cigarette; the best single indicator of tobacco dependence. Monaldi Arch. Chest Dis. 2003; 59: 95-98.

80. Etter J.F., Duc T.V., Perneger T.V. Saliva cotinine levels in smokers and nonsmokers. Am. J. Epidemiol. 2000; 151: 251-258.

81. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br. J. Addict. 1991; 86: 1119-1127.

82. Fagerström K.O., Schneider N. Measuring nicotine dependence: A review of the Fagerström tolerance questionnaire. J. Behav. Med. 1989; 12: 159-182.

83. Breslau N., Johnson E.O. Predicting smoking cessation and major depression in nicotine dependent smokers. Am. J. Publ. Hlth 1999; 90: 1122-1127.

84. Batra A., Gelfort G., Bartels M. The dopamine D2 receptor (DRD2) gene - a genetic risk factor in heavy smoking? Addict. Biol. 2000; 5: 431-438.

85. Etter J.F., LeHouezec J., Perneger T.V. A self-administered questionnaire to measure addiction to cigarettes. The Cigarette Dependence Scale. Neuropsychopharmacology 2003; 28: 359-370.

86. Javors M.A., Hatch J.P., Lamb R. Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction 2005; 100: 159-167.

87. Jimenez-Ruiz C.A., Masa F., Miravitlles M. et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365-1370.

88. Petty T.L., Doherty D.E. National Lung Health Education Program. The National Lung Health Education Program: roots, mission, future directions. Respir. Care 2004; 49: 678-683.

89. Enright P.L., Kaminsky D.A. Strategies for screening for chronic obstructive pulmonary disease. Respir. Care 2003; 48: 1194-1201.

90. Clotet J., Gomez-Arbones X., Ciria C., Aldalad J.M. Spirometry is a good method for detecting and monitoring chronic obstructive pulmonary disease in highrisk smokers in primary care. Arch. Bronconeumol. 2004; 40: 155-159.

91. Stratelis G., Jakobsson P., Molstad S., Zetterstrom O. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. Br. J. Gen. Pract. 2004; 54: 201-206.

92. Gorecka D., Bednarek M., Nowinski A. et al. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916-1923.

93. Bize R., Burnand B., Mueller Y., Cornuz J. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst. Rev. 2005; 4: CD0004705.

94. Hughes J.R. Comorbidity and smoking. Nicotine Tob. Res. 1999; 1 (suppl. 2): S149-S152.

95. Dierker L.C., Avenevoli S., Stolar M., Merikangas K.R. Smoking and depression: an examination of mechanisms of comorbidity. Am. J. Psychiatry 2002; 159: 947-953.

96. Glassman A.H., Covey L.S., Stetner F., Rivelli S. Smoking cessation and the source of major depression: a follow up study. Lancet 2001; 357: 1929-1932.

97. Wagena E., Kant I., Huibers M.J. et al. Psychological distress and depressed mood in employees with asthma, chronic bronchitis or emphysema: a populationbased observational study on prevalence and the relationship with smoking cigarettes. Eur. J. Epidemiol. 2004; 19: 147-153.

98. Arrol B., Khin N., Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. Br. Med. J. 2003; 327: 1144-1146.

99. Watkins C., Daniels L., Jack C. et al. Accuracy of a single question in screening for depression in a cohort of patients after stroke: comparative study. Br. Med. J. 2001; 323: 1159.

100. Centers for Disease Control and Prevention. Smoking cessation during previous years among adults in United States 1990 and 1991. Morbid. Mortal. Wkly Rep. 1993; 42: 504-507.

101. US Department of Health and Human Services. The health consequences of smoking: Chronic obstructive lung disease. A report of the Surgeon General. Rockville: US Department of Health and Human Services; 1984.

102. van Manen J.G., Bindels P.J., Dekker F.W. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002; 57: 412-416.

103. Wagena E.J., Kant I., van Amelsvoort L.G. et al. Risk of depression and anxiety in employees with chronic bronchitis: the modifying effect of cigarette smoking. Psychosom. Med. 2004; 66 (5): 729-734.

104. Breslau N., Peterson E.L., Schultz L.R. Major depression and stages of smoking. A longitudinal investigation. Arch. Gen. Psychiatry 1998; 55: 161-166.

105. Covey L.S., Glassaman A.H., Stetner F. Cigarette smoking and major depression. J. Addict. Dis. 1998; 17: 35-46.

106. West R., Hajek P., Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol. Med. 1989; 19: 981-985.

107. Shiffman S., Hickcox M., Paty J. et al. Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J. Consult. Clin. Psychol. 1996; 64: 993-1002.

108. Kim H.F., Kunik M.E., Molinari V.A. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000; 41: 465-471.

109. de Voogd J.N., Elzen H.A. Psychological state and personality traits of patients in a pulmonary rehabilitation program. Eur. Respir. J. 2001; 18: (suppl. 33): 54s.

110. Dudley D.L., Wermuth C., Hague W. Psychological aspects of care in the chronic obstructive pulmonary disease patient. Heart Lung 1973; 2: 339-345.

111. Gorecka D., Bednarek M., Nowinski A. et al. Nicotine dependence in smokers at risk for COPD. Eur. Respir. J. 2002; 20: (suppl. 38): 134s.

112. Miloskovic V., Lazic Z. Lung function and level of the smoker's nicotine dependence. Eur. Respir. J. 2001; 18: (suppl. 33): S115-S116.

113. Kunze U., Schoberberger R., Schmeiser-Rieder A., Fagerström K. Preventive oncology and nicotine addiction. In: Antypas G., ed. International proceedings division, 2nd International congress on lung cancer. Bologna: Monduzzi Editore; 1996: 551-554.

114. Mikami I., Akechi T., Kugaya A. et al. Screening for nicotine dependence among smoking-related cancer patients. Jpn. J. Cancer Res. 1999; 90: 1071-1075.

115. Jimenez-Ruiz C.A., Miravitlles M., Sobradillo V. et al. Can cumulative tobacco consumption, FTND score, and carbon monoxide concentrations in expired air be predictors of chronic obstructive pulmonary disease? Nicotine Tob. Res. 2004; 6: 649-653.

116. Medici T.C., Unger S., Ruegger M. Smoking pattern of smokers with and without tobacco-related lung diseases. Am. Rev. Respir. Dis. 1985; 131: 385-388.

117. Pauwels R.A., Buist A.S., Calverley P.M. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.

118. Siafakas N.M., Vermeire P., Pride N.B. et al. Optimal assessment and management of COPD. Eur. Respir. J. 1995; 8: 1398-1420.

119. Gray-Donald K., Gibbons L., Shapiro S.H. et al. Nutritional status and mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153: 961-966.

120. Filozof C., Fernadez Pinilla M.C., Fernadez-Cruz A. Smoking cessation and weight gain. Obes. Rev. 2004; 5: 95-103.

121. Lancaster T., Stead L.F. Self-help interventions for smoking cessation. Cochrane Database Syst. Rev. 2005; 3: CD001118.

122. Borland R., Balmford J., Hunt D. The effectiveness of personally tailored computer generated advice letters for smoking cessation. Addiction 2004; 99: 369-377.

123. Quist-Paulsen P., Gallefos F. Randomised controlled trial of smoking cessation intervention after admission for coronary heart disease. Br. Med. J. 2003; 327: 1254-1257.

124. Aveyard P., Griffin C., Lawrence T., Cheng K.K. A controlled trial of an expert system and self-help manual intervention based on the stages of change versus standard self-help materials in smoking cessation. Addiction 2003; 98: 345-354.

125. Lancaster T., Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; 4: CD000165.

126. Rice V., Stead L.F. Nursing interventions for smoking cessation. Cochrane Database Syst Rev 2004; 1: CD001188.

127. British Thoracic Society. Comparison of four methods for smoking cessation in patients with smoking related disorders. Br. Med. J. 1983; 286: 595-597.

128. Lancaster T., Stead L.F. Individual behavioural counseling for smoking cessation. Cochrane Database Syst. Rev. 2005; 2: CD001292.

129. Stead L.F., Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst. Rev. 2005; 2: CD001007.

130. Lichtenstein E., Glasgow R.E., Lando H.A. et al. Telephone counseling for smoking cessation: rationales and meta-analytic review of evidence. Hlth Educ. Res. 1996; 11: 243-257.

131. Stead L.F., Lancaster T., Perera R. Telephone counseling for smoking cessation. Cochrane Database Syst. Rev. 2006; 3: CD002850.

132. Borland R., Segan C.J., Livingston P.M., Owen N. The effectiveness of callback counselling for smoking cessation: a randomised trial. Addiction 2001; 96: 881-889.

133. Macleod Z.R., Charles M.A., Arnaldi V.C., Adams I.M. Telephone counselling as an adjunct to nicotine patches in smoking cessation: a randomised controlled trial. Med. J. Aust. 2003; 179: 349-352.

134. Hajek P., Stead L.F. Aversive smoking for smoking cessation. Cochrane Database Syst. Rev. 2001; 3: CD000546.

135. Ussher M., Nunciata P., Cropley M., West R. Effect of a short bout of exercise on tobacco withdrawal symptoms and desire to smoke. Psychopharmacology 2001; 158: 66-72.

136. Bock B.C., Marcus B.H., King T.K. et al. Exercise effects on withdrawal and mood among women attempting smoking cessation. Addict Behav. 1999; 24: 399-410.

137. Steptoe A., Edwards S., Moses J., Mathews A. The effects of exercise training on mood and perceived coping ability in anxious adults from the general population. J. Psychosom. Res. 1989; 33: 537-547.

138. McAuley E., Mihalko S.L., Bane S.M. Exercise and selfesteem in middle-aged adults: multidimensional relationships and physical fitness and self-efficacy influences. J. Behav. Med. 1997; 20: 67-83.

139. Ussher M. Exercise interventions for smoking cessation. Cochrane Database Syst. Rev. 2005; 1: CD002295.

140. Silagy C., Lancaster T., Stead L. et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2004; 3: CD000146.

141. Hughes J.R., Stead L.F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev. 2004; 4: CD000031.

142. Crowley T.J., Macdonald M.J., Walter M.I. Behavioural antismoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology 1995; 119: 193-204.

143. Pederson L.L., Wanklin J.M., Lefcoe N.M. The effect of counselling on smoking cessation among patients hospitalised with chronic obstructive pulmonary disease: a randomised clinical trial.Int. J. Addict. 1991; 26: 107-119.

144. Wagena E.J., van der Meer R.M., Ostelo R.J. et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir. Med. 2004; 98: 805-815.

145. Research Committee of the British Thoracic Society. Smoking cessation in patients: two further studies by the British Thoracic Society. Thorax 1990; 45: 835-840.

146. To/nnnesen P., Mikkelsen K.L. Routine smoking cessation with four nicotine regiments in a lung clinic. Eur. Respir. J. 2000; 16: 717-722.

147. West R., McNeill A., Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55: 987-999.

148. World Health Organisation. European partnership to reduce tobacco dependence: WHO evidence based recommendations on the treatment of tobacco dependence. Geneva, WHO, 2001.

149. National Institute for Health and Clinical Excellence. Smoking cessation - bupropion and nicotine replacement therapy. National Institute for Health and Clinical Excellence Technology appraisal TA39. Date last accessed: May 2006. Date last updated: March 2002.

150. Andersson J.E., Jorenby D.E., Scott W.J., Fiore M.C. Treating tobacco use and dependence. Chest 2002; 121: 932-941.

151. Wagena E., Zeegers M., Van Schayck C., Wouters E. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf. 2003; 26: 381-403.

152. Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. J.A.M.A. 1994; 272: 1497-1505.

153. Sachs D.P.L., Benowitz N.L., Silver K.J. Effective use of nicotine polacrilex (Nicorette) in patients with chronic obstructive pulmonary disease. In: Aoki M., Hisamichi S., Tominaga S., eds. Smoking and health. Amsterdam: Elsevier; 1987. 793-795.

154. Glover E.D., Glover P.N., Abrons H.L. et al. Smoking cessation among COPD and chronic bronchitis patients using the nicotine nasal spray. Am. J. Hlth Behav. 1997; 21: 310-317.

155. To/nnnesen P. Smoking cessation. In: Pauwels RA, Postma DS, Weiss ST, eds. Long-term intervention in chronic obstructive pulmonary disease. Lung Biol. Hlth Dis. Vol. 191. New York: Marcel Dekker; 2005. 315-352.

156. Campell I.A., Prescott R.J., Tjeder-Burton S.M. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum. Respir. Med. 1991; 85: 155-157.

157. Campbell I.A., Prescott R.J., Teder-Burton S.M. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. Respir. Med. 1996; 90: 47-51.

158. Miller N.H., Smith P.M., DeBusk R.F. et al. Smoking cessation in hospitalized patients: results of a randomized trial. Arch. Intern. Med. 1997; 157: 409-415.

159. Lewis S.F., Piasecki T.M., Anderson J.E., Baker T.B. Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. Prev. Med. 1998; 27: 296-303.

160. To/nnnesen P, Mikkelsen K.L., Markholst C. et al. Nurseconducted smoking cessation with minimal intervention in a lung clinic: a randomized controlled study. Eur. Respir. J. 1996; 9: 2351-2355.

161. To/nnnesen P., Mikkelsen K., Bremann L. Nurseconducted smoking cessation in patients with COPD, using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 314-316.

162. Gratziou C., Francis K., Maragianni A. et al. Bupropion treatment and cognitive behavioral therapy in smoking cessation program. Eur. Respir. J. 2001; 18: (suppl. 33): 12s.

163. Richmond R., Zwar N. Review of bupropion for smoking cessation. Drug Alcohol Rev. 2003; 22: 203-220.

164. To/nnnesen P., Fryd V., Hansen M. et al. Two and four mg nicotine chewing gum and group counseling in smoking cessation: An open, randomized, controlled trial with a 22 month follow-up. Addict Behav. 1988; 13: 17-27.

165. To/nnnesen P., Paoletti P., Gustavsson G. et al. Higher dosage nicotine patches increase oneyear smoking cessation rates: results from the European CEASE-trial. Eur. Respir. J. 1999; 13: 238-246.

166. Shiffman S., Dressler C., Hajek P. et al. Efficacy of a nicotine lozenge for smoking cessation. Arch. Intern. Med. 2002; 162: 1267-1276.

167. Ferry L.H., Burchette R.J. Efficacy of bupropion for smoking cessation in non-depressed smokers. J. Addict. Disord. 1994; 13: 249.

168. Dalsgareth O., Hansen N., Soes-Petersen U. et al. A multicentre, randomised, double blind, placebo controlled, 6-month trial of bupropion hydrochloride sustained release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob. Res. 2004; 6: 55-61.

169. Garcia-Rio F., Serrano S., Mediano O. et al. Safety profile of bupropion for COPD. Lancet 2001; 358: 1009-1010.

170. Tonstad S., Farsang D., Klaene G. et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur. Heart J. 2003; 24: 946-955.

171. Hays J.T., Hurt R.D., Rigotti N.A. et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann. Intern. Med. 2001; 135: 423-433.

172. Sampablo I., Lores L., CollKlein F. et al. Predictive factors in smoking cessation with combined therapy with bupropion and nicotine patches. Monaldi Arch. Chest Dis. 2003; 59: 171-176.

173. Jorenby D.E., Leischow S.J., Nides M.A. et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999; 340: 685-691.

174. Glassman A.H., Covey L.S., Dalack G.W. et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin. Pharmacol. Ther. 1993; 54: 670-679.

175. Hilleman D.E., Mohiuddin S.M., Delcore M.G., Lucas B.D. Jr. Randomized controlled trial of transdermal clonidine for smoking cessation. Ann. Pharmacother. 1993; 27: 1025-1028.

176. Gonzales D., Rennard S.I., Nides M. et al. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. J.A.M.A. 2006; 296: 47-55.

177. Jorenby D.E., Hays T., Rigotti N.A. et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. J.A.M.A. 2006; 296: 56-63.

178. Tonstad S., To/nnnesen P., Hajek P. et al. Effect of maintenance therapy with varenicline on smoking cessation. J.A.M.A. 2006; 296: 64-71.

179. Cohen C., Kodas E., Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol. Biochem. Behav. 2005; 81: 387-395.

180. Anthenelli R.M., Despres J.P. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (smoking cessation in smokers motivated to quit). In: American College of Cardiology. 53rd Annual scientific session. New Orleans: American College of Cardiology; 2004.

181. Van Gaal L.F., Rissanen A.M., Scheen A.J. et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1364.

182. White A., Resch K., Ernst E. A metanalysis of acupuncture techniques for smoking cessation. Tob. Control. 1999; 8: 393-397.

183. Yiming C., Changxin Z., Ung W.S. et al. Laser acupuncture for adolescent smokers - a randomised, double-blind controlled trial. Am. J. Chin. Med. 2000; 28: 443-449.

184. Abbot N.C., Stead L.F., White A.R. et al. Hypnotherapy for smoking cessation. Cochrane Database Syst. Rev. 1998; 2: CD001008.

185. Bolliger C.T., Zellweger J.P., Danielsson T. et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. Br. Med. J. 2000; 321: 329-333.

186. Wennike P., Danielsson T., Landfeldt T. et al. Smoking reduction promotes smoking cessation: Results from a double blind, randomised, placebo-controlled trial of nicotine gum with 2year followup. Addiction 2003; 98: 1395-1402.

187. Hughes J.R., Cummings K.M., Hyland A. Ability of smokers to reduce their smoking and its association with future smoking cessation. Addiction 1999; 94: 109-114.

188. Gotfredsen N., Prescott E., Osler M., Vestbo J. Predictors of smoking reduction and cessation in a cohort of Danish moderate and heavy smokers. Prev. Med. 2001; 33: 46-52.

189. To/nnnesen P., Danielsson T. Cutting down smoking then stopping with nicotine replacement therapy: an innovative approach to smoking cessation. Thorax 2005; 60 (suppl. II): ii36.

190. Hughes J.R., Carpenter M.J. Can medications or behavioral treatment reduce smoking in smokers not trying to quit? A review. In: Proceedings of the Society for Research on Nicotine and Tobacco 2005: 8.Hughes J.R. Smoking reduction: efficacy and implementation. Addiction 2000; 95 (suppl. 1): S3-S37.

191. Bates C., McNeill A., Jarvis M., Gray N. The future of tobacco product regulation and labelling in Europe: Implications for the forthcoming European Union directive. Tob. Control 1999; 8: 225-235.

192. Fagerström K.O., Hughes J.R., Rasmussen T., Callas P.W. Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tob. Control 2000; 9: 327-333.

193. Gray N., Henningfield J.E., Benowitz N.L. et al. Toward a comprehensive long term nicotine policy. Tob. Control 2005; 14: 161-165.

194. Glynn T.J., Manley M.W. How to help your patients to stop smoking: A National Cancer Institute Manual for Physicians. NIH Publication № 93-3064. Bethesda: National Institutes of Health; 1993.

195. Prochaska J.O., Goldstein M.G. Process of smoking cessation. Implications for clinicians. Clin. Chest Med. 1991; 12: 727-735.

196. Jarvis M.J., Russell M.A., Saloojee Y. Expired air carbon monoxide: a simple breath test of tobacco smoke intake. Br. Med. J. 1980; 281: 484-485.

197. Heffner J.E. The overarching challenge. Chest 2000; 118 (suppl. 2): 1S-3S.

198. Smith W.R. Evidence for the effectiveness of techniques to change physician behavior. Chest 2000; 118 (suppl. 2): 8S-17S.

199. Heffner J.E., Alberts W.M., Irwin R., Wunderink R. Translating guidelines into clinical practice. Recommendations to the American College of Chest Physicians. Chest 2000; 118 (suppl. 2): 70S-73S.

200. Nardini S., Bertoletti R., Rastelli V., Donner C.F. The influence of personal tobacco smoking on the clinical practice of Italian chest physicians. Eur. Respir. J. 1998; 12: 1450-1453.

201. European SmokeFree Hospital Network. Date last accessed: November 28, 2006. Date last modified: November 23, 2006.

202. Johnson E., Dominici F., Griswold M., Zeger S.L. Disease cases and their medical costs attributable to smoking: an analysis of the national medical expenditure survey. J. Economet. 2003; 112: 135-151.

203. Barendregt J.J., Bonneux L., van der Maas J. The health care costs of smoking. N. Engl. J. Med. 1997; 337: 1052-1057.

204. Ruff L.K., Volmer T., Nowak D., Meyer A. The economic impact of smoking in Germany. Eur. Respir. J. 2000; 16: 385-390.

205. Parrott S., Godfrey C., Raw M. et al. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 1998; 53 (suppl. 5): S1-S38.

206. Godfrey C. The economic and social costs of lung cancer and the economics of smoking prevention. Monaldi Arch. Chest Dis. 2001; 56: 458-461.

207. World Health Organization. Economic Consequences of Smoking (ECOS) model. WHO European Partnership Project to Reduce Tobacco Dependence. Copenhagen; Geneva: World Health Organization; 1999.

208. Lazzaro C. Health and Economic Consequences of Smoking (ECOS) model. WHO European Partnership Project to Reduce Tobacco Dependence. Appendix 1. Copenhagen-Geneva, World Health Organization, 1999.

209. Parrott S., Godfrey C., Raw M. Costs of employee smoking in the workplace in Scotland. Tob. Control 2000; 9: 187-192.

210. Drummond M.F., O'Brien B.J., Stoddart G.L., Torrance G.W. Methods for the economic evaluation of health care programmers, 2nd ed. Oxford: Oxford University Press; 1997. 109-112.

211. Gold M.R., Siegel J.E., Russel L.B., Weinstein M.C. Cost effectiveness in health and medicine. New York: Oxford University Press; 1996.

212. Maynard A. Developing the health care market. Econ. J. 1991; 101: 1277-1286.

213. Schulmann K.A., Lorna A.L., Glick H.A., Eisenberg J. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 1991; 114: 798-802.

214. Rutten-Van Mölken M.P.M.H., Van Doorslaer E.K.A., Rutten F.F.H. Economic appraisal of asthma and COPD care: a literature review 1980-1981. Soc. Sci. Med. 1992; 35: 161-175.

215. Cromwell J., Bartosch W.J., Fiore M.C. et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. J.A.M.A. 1997; 278: 1759-1766.

216. Department of Health. Independent inquiry into inequalities in health. London: Stationery Office; 1998.

217. NHS Centre for Reviews & Dissemination. A rapid and systematic review of the clinical and cost effectiveness of bupropion SR and nicotine replacement therapy (NRT) for smoking cessation. York: University of York; 2002.

218. Invernizzi G., Nardini S., Bettoncelli G. et al. L'intervento del medico di medicina generale nel controllo del fumo. Rassegna Patol. Appar. Respir. 2002; 17: 55-70.

219. Baker D., Illsley R. Inequalities in health. Studies in inequality in health need careful interpretation. Br. Med. J. 1998; 317: 1659.

220. Whitfield L. Social policies ''must focus on inequalities''. Hlth Serv. J. 1998; 108: 8.

221. Harris J.E., Chan S.W. The continuum-of-addiction: cigarette smoking in relation to price among Americans aged 15-29. Hlth Econ. 1999; 8: 81-86.

222. Becker G.S., Murphy K.M. A theory of rational addiction. J. Politic. Economy 1988; 96: 675-700.

223. Becker G.S., Grossman M., Murphy K.M. An empirical analysis of cigarette addiction. Am. Econ. Rev. 1994; 84: 396-418.

224. Chaloupka F.J., Tauras J., Grossman M. Economic models of addiction and applications to cigarette smoking and other substance abuse. Chicago: University of Illinois; 1999. 1-27.

225. Chaloupka F.J. Tobacco taxation. generalarea_PDFs/NCSLSEATTLE111601.pdf. Date last accessed: September 22, 2006.

226. Chaloupka F.J. Price, tobacco control policies and youth and young adult tobacco use. TUPTI082401.pdf. Date last accessed: September 22, 2006.

227. Cornuz J., Gilbert A., Pinget C. et al. Costeffectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tobacco Control 2006; 15: 152-159.


Для цитирования:

Тоннесен П..., Карроззи Л..., Фагерстрем К.О., Грациу К..., Хименезруиз К..., Нардини С..., Виеджи Д..., Лаццаро К..., Кэмпелл И.А., Дагли Е..., Вест Р... Отказ от курения у больных с респираторными заболеваниями: первоочередной компонент лечения. Пульмонология. 2010;(2):9-36.

Просмотров: 89

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)